Summary
Indomethacin 0, 15, 25 and 35 mg t. i. d. was given in randomized order for two weeks to eight outpatients with rheumatoid arthritis in a double-blind study. At the end of each treatment period the clinical response was evaluated by subjective and objective methods and the plasma indomethacin concentration was measured by GLC-mass fragmentography. Compared with non-treatment periods, indomethacin had a statistically significant therapeutic effect as judged by global assessment, duration of morning stiffness, use of escape analgesia, articular index and pain score, but there was no relation between the clinical effect and the size of the dose or the plasma concentration of the drug. Technetium uptake over the affected joints did not change during indomethacin therapy, which might reflect a lack of effect on the local activity of the disease. Lower doses than those currently prescribed are probably sufficient to alleviate symptoms in this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alván G, Orme ML'E, Bertilsson L, Ekstrand R, Palmér L (1975) Pharmacokinetics of indomethacin. Clin Pharmacol Ther 3: 364–373
van Arman CG, Nuss GW, Risley EA (1973) Interactions of aspirin, indomethacin and other drugs in adjuvant-induced arthritis in the rat. J Pharmacol Exp Ther 2: 400–414
Armitage P (1971) Statistical methods in medical research. Blackwell, Oxford, pp 131–134
Baber N, Halliday L, Sibeon R, Littler T, Orme ML'E (1978) The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. Clin Pharmacol Ther 3: 298–307
Baber N, Halliday LDC, VandenHeuvel WJA, Walker RW, Sibeon R, Keenan JP, Littler T, Orme ML'E (1979) A study of indomethacin in rheumatoid arthritis. Clinical effects, pharmacokinetics and platelet studies in responders and non-responders. Ann Rheum Dis 38: 128–136
Boardman PL, Hart FD (1967) Clinical measurement of the antiinflammatory effect of salicylates in rheumatoid arthritis. Br Med J 4: 264–268
Collins KE, Deodhar S, Nuki G, Whaley K, Buchanan WW, Dick WC (1971): Radioisotope study of small joints inflammation in rheumatoid arthritis. Ann Rheum Dis 30: 401–405
Dick WC, Neufeld RR, Prentice AG, Woodburn A, Whaley K, Nuki G, Buchanan WW (1970) Measurement of joint inflammation. A radioisotopic method. Ann Rheum Dis 29: 135–137
Dick WC, Grayson MF, Woodburn A, Nuki G, Buchanan WW (1970) Indices of inflammatory activity. Relationship between isotope studies and clinical methods. Ann Rheum Dis 29: 643–648
Documenta Geigy (1970) 7th Ed. Basel, pp 155, 169
Donnelly P, Lloyd K, Campbell H (1967) Indomethacin in rheumatoid arthritis: An evaluation of its anti-inflammatory and side effects. Br Med J 1: 69–75
Ferreira SH, Moncada S, Vane JR (1974) Prostaglandins and signs and symptoms of inflammation. In: Robinson HJ, Vane JR (eds) Prostaglandin synthetase inhibitors. Raven Press, New York, pp 175–187
Joyce CRB, Zutshi DW, Hrubes V, Mason RM (1975) Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol 8: 415–420
Oka M, Rekonen A, Ruotsi A (1971) Tc99m in the study of systemic inflammatory activity in rheumatoid arthritis. A preliminary report. Acta Rheumatol Scand 17: 27–30
Oka M, Rekonen A, Ruotsi A, Kuikka J (1973) Measurement of systemic inflammatory activity in rheumatoid arthritis by the99mTc method. Scand J Rheumatol 2: 101–107
Orme M, Holt PJL, Hughes GRV, Bulpitt CJ, Draffan GH, Thorgeirsson SS, Williams F, Davies DS (1976) Plasma concentration of phenylbutazone and its therapeutic effects — studies in patients with rheumatoid arthritis. Br J Clin Pharmacol 3: 185–191
Palmér L, Bertilsson L, Alván G, Orme ML'E, Sjöqvist F, Holmstedt B (1974) Indomethacin: Quantitative determination in plasma by mass fragmentography including pilot pharmacokinetics in man. In: Robinson HJ, Vane JR (eds) Prostaglandin synthetase inhibitors. Raven Press, New York, pp 91–97
Physicians' Desk Reference (1978) Medical Economics Company, Oradell, NJ
Pinals RS, Frank S (1967) Relative efficacy of indomethacin and acetylsalicylic acid in rheumatoid arthritis. N Engl J Med 276: 512–514
Pitkeathly DA, Banerjee NR, Harris R, Sharp J (1966) Indomethacin in inpatient treatment of rheumatoid arthritis. Ann Rheum Dis 25: 334–339
Rane A, Oelz O, Frolich JC, Seyberth HW, Sweetman BJ, Watson JT, Wilkinson GR, Oates JA (1978) Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther 6: 658–668
Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW (1968) Clinical studies with an articular index for treatment of joint tenderness in patients with rheumatoid arthritis. Qu J Med 37: 393–406
Ropes MW, Bennet GA, Cobb S, Jacox R, Jessar RA (1959) Revision of diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis 18: 49–53
Szanto E, Rudén B.-J (1976)99mTc in evaluation of sacro-iliac arthritis. Scand J Rheumatol 5: 11–15
Szanto E (1979) Quantitative99mTc-pertechnetate scanning of the sacro-iliac joint. Dissertation at the Karolinska Institute, Stockholm
Wanka J, Jones LI, Wood PHN, Dixon ASJ (1964) Indomethacin in rheumatic diseases: A controlled clinical trial. Ann Rheum Dis 23: 218–225
Ward JR (1964) Rheumatoid arthritis: Evaluation of disease activity and response to indomethacin therapy. International symposium on non-steroidal anti-inflammatory drugs. Amsterdam, Excerpta Medica 82: 355–360
Weber E (1973) Nonparametric methods: The sign test. In: Delaunois AL (ed) Biostatistics in pharmacology. Pergamon Press, Oxford, pp 919–923.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ekstrand, R., Alván, G., Orme, M.L. et al. Double-blind dose-response study of indomethacin in rheumatoid arthritis. Eur J Clin Pharmacol 17, 437–442 (1980). https://doi.org/10.1007/BF00570161
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00570161